Halozyme Therapeutics elects James Daly to board
James Daly’s board term ends at Halozyme’s 2029 annual meeting; he was not initially assigned to a committee.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Halozyme Therapeutics (HALO) elected James Daly to its Board of Directors on September 28, 2026. His term is in the director class ending at the 2029 annual meeting, and he was not initially assigned to a Board committee. Daly will receive compensation under the program for non-employee directors, which currently includes cash retainers for Board and committee service, restricted stock and stock option awards. The company stated that no arrangements or understandings led to his election and that there are no related person transactions between the company and Daly.
Insights
Analyzing...
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Election date: September 28, 2026
Board term: Annual meeting in 2029
2 metrics
Election date
September 28, 2026
James Daly elected to the Board
Board term
Annual meeting in 2029
Director class to which James Daly was elected
Key Terms
director compensation program, restricted stock, stock option awards, related person transactions
4 terms
director compensation program financial
"under our director compensation program applicable to all non-employee directors"
restricted stock financial
"cash retainers for Board and committee service, restricted stock"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
stock option awards financial
"restricted stock and stock option awards"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who joined HALO’s board, and when?
James Daly was elected to Halozyme Therapeutics’ Board of Directors on September 28, 2026. His term is in the class ending at the company’s 2029 annual meeting, and he was not initially assigned to a Board committee.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | ||||||||
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||||||
| (Zip Code) | ||||||||
| (Address of principal executive offices) | ||||||||
(858 ) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2029 and was not initially assigned to any Board committee. Mr. Daly will receive compensation for his services (currently consisting of cash retainers for Board and committee service, restricted stock and stock option awards) under our director compensation program applicable to all non-employee directors, as revised from time to time. The current components of the non-employee director compensation program were described in our proxy statement for the 2026 Annual Meeting of Stockholders held on May 5, 2026
There are no arrangements or understandings pursuant to which Mr. Daly was elected as a director and there are no related person transactions between the Company and Mr. Daly.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Halozyme Therapeutics, Inc (Registrant) | |||||||||||||||||
Dated: | September 30, 2026 | By: | /s/ Mark Snyder | ||||||||||||||
| Mark Snyder | |||||||||||||||||
| Executive Vice President, Chief Legal Officer and Corporate Secretary | |||||||||||||||||